Болезнь Паркинсона и мигрень

Болезнь Паркинсона (БП) – одно из наиболее частых нейродегенеративных заболеваний. Мигрень – наиболее распространенное неврологическое заболевание взрослых. Установлено, что мигрень часто предшествует развитию БП, а с дебютом моторных проявлений и/или началом специфической терапии частота и выраженность приступов мигрени значительно снижаются. Вероятно, оба заболевания имеют общие функциональные и биохимические черты. Если дезинтеграция ядер ствола мозга и дизрегуляция дофаминергической нейропередачи имеют отношение к патогенезу мигрени, то исследование пациентов с мигренью, у которых развивается БП, может предоставить важную информацию о роли дофамина и/или дофаминергических областей ствола мозга в патогенезе как мигрени, так и БП. Обзор посвящен исследованиям эпидемиологии, роли генов дофаминергической системы в развитии мигрени, механизмам взаимосвязи обоих заболеваний и влиянию медикаментозной терапии.

1. Азимова ЮЭ, Амелин АВ, Алферова ВВ и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1-3):4-36. doi: 10.17116/jnevro20221220134

2. Ali MD, Gayasuddin Qur F, Alam MS, et al. Global Epidemiology, Clinical Features, Diagnosis and Current Therapeutic Novelties in Migraine Therapy and their Prevention: A Narrative Review. Curr Pharm Des. 2023;29(41):3295-311. doi: 10.2174/0113816128266227231205114320

3. Шток ВН, Иванова-Смоленская ИА, Левина ОС, редакторы. Экстрапирамидные расстройства. Руководство по диагностике и лечению. Москва: МЕДпресс-информ, 2002. 608 с.

4. Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/716_1 [Parkinson’s disease, secondary parkinsonism and other diseases that manifest as parkinsonism syndrome. Clinical Recommendations. 2021. Available at: https://cr.minzdrav.gov.ru/recomend/716_1 (In Russ.)].

5. Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi: 10.1007/s00702-017-1686-y. Epub 2017 Feb 1.

6. Ashina S, Bentivegna E, Martelletti P, Eikermann-Haerter K. Structural and Functional Brain Changes in Migraine. Pain Ther. 2021 Jun;10(1):211-23. doi: 10.1007/s40122-021-00240-5. Epub 2021 Feb 16.

7. Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurol Sci. 2013 May;34 Suppl 1:S67-70. doi: 10.1007/s10072-013-1415-8

8. Ha WS, Kim J, Hwang HW, et al. The association between migraine and Parkinson's disease: a nationwide cohort study. Epidemiol Health. 2024;46:e2024010. doi: 10.4178/epih.e2024010. Epub 2023 Dec 18.

9. Todt U, Netzer C, Toliat M, et al. New genetic evidence for involvement of the dopamine system in migraine with aura. Hum Genet. 2009 Apr;125(3):265-79. doi: 10.1007/s00439-009-0623-z. Epub 2009 Jan 17.

10. Fernandez F, Lea RA, Colson NJ, et al.Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci. 2006 Dec 21;251(1-2):118-23. doi: 10.1016/j.jns.2006.09.013. Epub 2006 Nov 7.

11. Сергеев АВ, Гузий ЕА, Ковальчук НАи др. Роль генов дофаминергической системы в развитии хронической мигрени и лекарственно-индуцированной головной боли. Российский журнал боли. 2024;22(4):24-9. doi: 10.17116/pain20242204124

12. Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's disease and its association with the side of motor symptom onset. Neurol Sci. 2014 Apr;35(4):595-600. doi: 10.1007/s10072-013-1571-x. Epub 2013 Nov 7.

13. Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in Parkinson's disease: A multicentre case-controlled study. Cephalalgia. 2018;38:1535-44. doi: 10.1177/0333102417739302

14. Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's disease and headaches: A cross-sectional study. Headache. 2020;60:967-73. doi: 10.1111/head.13815

15. Angelopoulou E, Papadopoulos AN,Spantideas N, Bougea A. Migraine, tensiontype headache and Parkinson's Disease: A systematic review and meta-analysis. Medicina. 2022;58:1684. doi: 10.3390/medicina58111684

16. Залялова ЗА, Яковлева ЛА, Алтунбаев РА. Болевой синдром при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2011;111(3):79-81.

17. Scher AI, Ross GW, Sigurdsson S, et al. Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. Neurology. 2014 Sep 30;83(14):1246-52. doi: 10.1212/WNL.0000000000000840. Epub 2014 Sep 17.

18. Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A population-based, propensity score-matched, longitudinal followup study. Cephalalgia. 2016 Dec;36(14):131623. doi: 10.1177/0333102416630577. Epub 2016 Feb 6.

19. De Oliveira Vilaca C, Leite MA, de Souza JA, et al. The Behavior of Migraine in Patients with Parkinson's Disease. Neurol Int. 2015 Dec 21;7(3):6133. doi: 10.4081/ni.2015.6133

20. Barbanti P, Fabbrini G, Vanacore N, et al.Dopamine and migraine: does Parkinson's disease modify migraine course? Cephalalgia. 2000 Oct;20(8):720-3. doi: 10.1111/j.1468-2982.2000.00123.x

21. Jatale V, Tiwari A, Kumar M, et al.Migraine and Tension-type Headache in Parkinson's Disease and Progressive Supranuclear Palsy/Corticobasal Syndrome. Ann Indian Acad Neurol. 2023 SepOct;26(5):708-14. doi: 10.4103/aian.aian_604_23. Epub 2023 Sep 25.

22. Jurado-Coronel JC, Cabezas R, Avila Rodriguez MF, et al. Sex differences in Parkinson's disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018 Jul;50:18-30. doi: 10.1016/j.yfrne.2017.09.002. Epub 2017 Sep 30.

23. Liampas I, Mylonas KS, Brotis A, et al. Serum lipid abnormalities in migraine: A meta-analysis of observational studies. Headache. 2021 Jan;61(1):44-59. doi: 10.1111/head.14039. Epub 2021 Jan 4.

24. Peroutka SJ, Wilhoit T, Jones K. Clinicalsusceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology. 1997 Jul;49(1):201-6. doi: 10.1212/wnl.49.1.201

25. Emin Erdal M, Herken H, Yilmaz M,Bayazit YA. Significance of the catechol-Omethyltransferase gene polymorphism in migraine. Brain Res Mol Brain Res. 2001 Oct 19;94(1-2):193-6. doi: 10.1016/s0169328x(01)00219-4

26. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006 Sep;13(9):1009-13. doi: 10.1111/j.1468-1331.2006.01415.x

27. Indo T, Naito A, Sobue I. Clinical characteristics of headache in Parkinson's disease. Headache. 1983 Sep;23(5):211-2. doi: 10.1111/j.1526-4610.1983.hed2305211.x

28. Meco G, Frascarelli M, Pratesi L, et al. Headache in Parkinson's disease. Headache. 1988 Feb;28(1):26-9. doi: 10.1111/j.13652524.1988.hed2801026.x

29. Van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clin Neurol Neurosurg. 1992;94 Suppl:S168-70. doi: 10.1016/0303-8467(92)90060-g

30. Cubo E, Kompoliti K, Leurgans SE,Raman R. Dopaminergic hypersensitivity in patients with Parkinson disease and migraine. Clin Neuropharmacol. 2004 Jan-Feb;27(1):30-2. doi: 10.1097/00002826-200401000-00009

31. Парфенов ВА, Пожидаев КА. Хроническая мигрень в пожилом возрасте. Клиническая геронтология. 2019;25(5-6):47-51. doi: 10.26347/1607-2499201905-06047-0151

32. Charbit AR, Akerman S, Goadsby PJ.Dopamine: what's new in migraine? Curr Opin Neurol. 2010;23:275-81. doi: 10.1097/WCO.0b013e3283378d5c

33. Akerman S, Goadsby PJ. Dopamine and migraine: biology and clinical implications. Cephalalgia. 2007 Nov;27(11):1308-14. doi: 10.1111/j.1468-2982.2007.01478.x

34. Page MJ, McKenzie JE, Bossuyt PM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71

35. Lin YK, Tsai CL, Lin GY, et al.Pathophysiology of Chronic Migraine: Insights from Recent Neuroimaging Research. Curr Pain Headache Rep. 2022 Nov;26(11):843-54. doi: 10.1007/s11916-022-01087-x. Epub 2022 Oct 7.

36. Niddam DM, Lai KL, Tsai SY, et al.Neurochemical changes in the medial wall of the brain in chronic migraine. Brain. 2018 Feb 1;141(2):377-90. doi: 10.1093/brain/awx331

37. Albrecht DS, Mainero C, Ichijo E, et al.Imaging of neuroinflammation in migraine with aura: a [11C]PBR28 PET/MRI study. Neurology. 2019;92:e2038-e2050. doi: 10.1212/WNL.0000000000007371

38. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994 Dec;50(4):1088-101.

39. Катунина ЕА, Залялова ЗА, Похабов ДВи др. Болезнь Паркинсона. Фокус на ранние стадии. Неврология, нейропсихиатрия, психосоматика. 2023;15(3):95-103. doi: 10.14412/2074-2711-2023-3-95-103

40. Antonini A, Tinazzi M, Abbruzzese G, et al.Pain in Parkinson's disease: facts and uncertainties. Eur J Neurol. 2018 Jul;25(7):917-e69. doi: 10.1111/ene.13624. Epub 2018 Apr 18.

41. Fox SH, Chuang R, Brotchie JM.Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord. 2009 Jul 15;24(9):1255-66. doi: 10.1002/mds.22473

42. Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. doi: 10.1007/s00441-0040956-9. Epub 2004 Aug 24.

43. Mendlin A, Martin FJ, Jacobs BL.Dopaminergic input is required for increases in serotonin output produced by behavioral activation: an in vivo microdialysis study in rat forebrain. Neuroscience. 1999;93(3):897-905. doi: 10.1016/s0306-4522(99)00213-4

44. Ashina S, Bendtsen L, Ashina M.Pathophysiology of tension-type headache. Curr Pain Headache Rep. 2005 Dec;9(6):415-22. doi: 10.1007/s11916-005-0021-8

45. Aggarwal M, Puri V, Puri S. Serotonin and CGRP in migraine. Ann Neurosci. 2012 Apr;19(2):88-94. doi: 10.5214/ans.0972.7531.12190210

46. Saengjaroentham C, Supornsilpchai W, Ji-Au W, et al. Serotonin depletion can enhance the cerebrovascular responses induced by cortical spreading depression via the nitric oxide pathway. Int J Neurosci. 2015 Feb;125(2):130-9. doi: 10.3109/00207454.2014.908876. Epub 2014 May 19.

47. Dusek P, Jankovic J, Le W. Iron dysregulation in movement disorders. Neurobiol Dis. 2012 Apr;46(1):1-18. doi: 10.1016/j.nbd.2011.12.054. Epub 2012 Jan 12.

48. Kruit MC, Launer LJ, Overbosch J, et al.Iron accumulation in deep brain nuclei in migraine: a population-based magnetic resonance imaging study. Cephalalgia. 2009 Mar;29(3):351-9. doi: 10.1111/j.14682982.2008.01723.x. Epub 2008 Nov 19.

49. Chen Z, Zhao H, Chen X, et al. The increased iron deposition of the gray matter over the whole brain in chronic migraine: An exploratory quantitative susceptibility mapping study. Mol Pain. 2022 JanDec;18:17448069221074987. doi: 10.1177/17448069221074987

50. Edvinsson L. Role of CGRP in migraine.Handb Exp Pharmacol. 2019;255:121-30. doi: 10.1007/164_2018_201

51. Raffaelli B, Storch E, Overeem LH, et al.Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023 Apr 25;100(17):e1825-e1835. doi: 10.1212/WNL.0000000000207114. Epub 2023 Feb 22.

52. Labastida-Ramirez A, Rubio-Beltran E,Villalon CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. Cephalalgia. 2019 Mar;39(3):435-44. doi: 10.1177/0333102417739584. Epub 2017 Oct 30.

53. Thornton E, Vink R. Substance P and itstachykinin NK1 receptor: a novel neuroprotective target for Parkinson's disease. Neural Regen Res. 2015 Sep;10(9):1403-5. doi: 10.4103/16735374.165505

54. Gimeno-Ferrer F, Eitner A, Bauer R, et al.From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex. Exp Neurol. 2022 Oct;356:114152. doi: 10.1016/j.expneurol.2022.114152. Epub 2022 Jun 26.

55. Di Angelantonio S, Giniatullin R, Costa V,et al. Modulation of neuronal nicotinic receptor function by the neuropeptides CGRP and substance P on autonomic nerve cells. Br J Pharmacol. 2003 Jul;139(6):1061-73. doi: 10.1038/sj.bjp.0705337

56. Svenningsson P, Palhagen S, Mathe AA. Neuropeptide Y and Calcitonin Gene-Related Peptide in Cerebrospinal Fluid in Parkinson's Disease with Comorbid Depression versus Patients with Major Depressive Disorder. Front Psychiatry. 2017 Jun 12;8:102. doi: 10.3389/fpsyt.2017.00102

57. Hamed SA. The vascular risk associationswith migraine: relation to migraine susceptibility and progression. Atherosclerosis. 2009 Jul;205(1):15-22. doi: 10.1016/j.atherosclerosis.2008.10.016. Epub 2008 Nov 1.

58. Красников АВ, Шведков ВВ, Шабалина АА, Костырева МВ. Диагностика дислипидемии при эпизодической мигрени. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(5):17-8. doi: 10.17116/pain2021190325

59. Hu G, Antikainen R, Jousilahti P, et al.Total cholesterol and the risk of Parkinson disease. Neurology. 2008 May 20;70(21):1972-9. doi: 10.1212/01.wnl.0000312511.62699.a8. Epub 2008 Apr 9.

60. Nam GE, Kim SM, Han K, et al.Metabolic syndrome and risk of Parkinson disease: a nationwide cohort study. PLoS Med. 2018;15:e1002640. doi: 10.1371/journal.pmed.1002640

61. Chen H, Zhang SM, Hernaan MA, et al. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol. 2003;157:1007-14. doi: 10.1093/aje/kwg073